Splice Variants CLDN18.2 and FGFR2b Emerge as Prime Cancer Drug Targets
A new review maps how two splice-variant proteins, CLDN18.2 and FGFR2b, became leading cancer drug targets, and why next-generation antibodies, ...
Tag: CLDN18
POPULAR NEWS
-
Alloys That Shrink Their Own Grains: New PIX Mechanism Refines Metals With Heat Alone
-
Endurance Exercise Reshapes the Liver in Males and Females Through Distinct Molecular Routes
-
Single Transcription Factor PU.1 Rapidly Converts Fibroblasts into Macrophage-Lineage Cells
-
New Scale Measures How Ready Nurse Educators Really Are for the AI Era